Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review
Authors:
Open Access
- 1 June 2016
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 3917-3923
Abstract
Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review Quansong Xia,1 Juan Xu,2 Huoying Chen,3 Yanzhang Gao,1 Feili Gong,3 Liya Hu,1 Li Yang1 1Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University, 2The People’s Hospital of Guandu District, Kunming, 3Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China Background: HMGB1 has been overexpressed in the tissues or serum of patients with non-small-cell lung cancer (NSCLC) in several studies. However, the results remain inconsistent. Objective: The aim of this study was to perform a meta-analysis to investigate the relationship between elevated level of HMGB1 and NSCLC. Methods: Associated studies were included, and the pooled risk difference and mean difference (MD) together with 95% confidence interval (CI) were calculated. Results: A total of ten relevant studies on HMGB1 expression were included in this meta-analysis. The pooled results suggested that the expression of HMGB1 in NSCLC tissues was notably higher than those in corresponding nontumor normal tissues by using immunohistochemistry (risk difference =0.38, 95% CI: 0.28–0.48, Z=7.67, P<0.00001, I2=0%), Western blot (MD =0.27, 95% CI: 0.06–0.47, Z=2.57, P<0.01), or real-time polymerase chain reaction (MD =15.15, 95% CI: 14.8–15.5, Z=2.08, P=0.04). Serum HMGB1 levels were similarly significantly higher in patients with NSCLC than those in healthy controls. The pooled MDs of HMGB1 in patients with NSCLC compared with healthy controls were 17.54 with 95% CI: 10.99–24.09, Z=5.25, P<0.00001. Two of the included studies were fully reviewed without performing meta-analysis due to the different detection methods used. The protein level of HMGB1 in patients with NSCLC of tumor, nodes, and metastasis (TNM) stages III–IV was higher than that of TNM stages I–II (P<0.047 and P<0.001, respectively). Conclusion: The expression levels of HMGB1 in both tissues and serum of patients with NSCLC were statistically higher than those of normal lung samples, which indicated that elevated levels of HMGB1 can reveal changes that correlated with disease progression, or even the risk of NSCLC disease progression. The elevated level of HMGB1 could also be considered as a potential biomarker for the diagnosis of patients with NSCLC. Keywords: HMGB1, non-small-cell lung cancer, meta-analysisKeywords
This publication has 35 references indexed in Scilit:
- High-mobility group box 1 accelerates early acute allograft rejection via enhancing IL-17+γδ T-cell responseTransplant International, 2014
- The Receptor for Advanced Glycation End-Products (RAGE) Protects Pancreatic Tumor Cells Against Oxidative InjuryAntioxidants & Redox Signaling, 2011
- Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancerCancer, 2011
- HMGB1 loves companyJournal of Leukocyte Biology, 2009
- HMGB1: Endogenous Danger SignalingMolecular Medicine, 2008
- The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunityImmunological Reviews, 2007
- High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenalNature Reviews Immunology, 2005
- Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomasVirchows Archiv, 2005
- HMGB proteins and gene expressionCurrent Opinion in Genetics & Development, 2003
- The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for AmphoterinJournal of Biological Chemistry, 1995